The firm said its remaining employees will focus on developing the pol theta inhibitor RP-3467 and the PLK4 inhibitor RP-1664.

ABI-201 is undergoing IND-enabling studies and uses the same capsid as the firm's clinical-stage gene therapy candidate for wet AMD.

The company said the move demonstrates the board of directors' confidence in the potential of its PARP1/2 inhibitor in ovarian cancer.

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...

Based on early Phase I/II data, investigators at Cincinnati Children's are enrolling more patients with a telomere biology ...

The first patient, who had xerostomia linked with Sjögren's disease, received the autologous cell therapy as part of a Phase ...

NEW YORK – AstraZeneca on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the HER2-targeted antibody-drug conjugate Enhertu (trastuzumab ...

NEW YORK – SciClone Pharmaceuticals has licensed exclusive rights to develop and distribute Eisai's FGFR selective tyrosine kinase inhibitor Tasfygo (tasurgratinib) in greater China. Tokyo-based Eisai ...

NEW YORK – Mustang Bio on Thursday said it ended the lease for its manufacturing facility and sold certain equipment from the facility to AbbVie for $1 million. As a result of the termination of its ...

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.